Researchers discover new immunotherapy combination effective at killing cancer cells – Medical Xpress
Medical Xpress |
Researchers discover new immunotherapy combination effective at killing cancer cells
Medical Xpress Immunotherapy is an emerging field in the global fight against cancer, even though scientists and clinicians have been working for decades to find ways to help the body’s immune system detect and attack cancerous cells. Doug Mahoney’s lab at the … New treatment eradicates cancer cells in Glasgow University studyBBC News Glasgow university scientists find new method of killing cancer cellsThe Times Anti-cancer breakthrough CICD can eradicate tumours, researchers saySky News |
|
CSL Behring to acquire stem cell therapy biotech firm
The Pharma Letter (registration) Blood products and vaccines specialist CSL Behring, a subsidiary of Australia’s CSL Limited (ASX: CSL), has agreed to acquire Calimmune, a US biotechnology company focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy … |
Technology Networks |
Stem Cell Treatment Helps Puppies With Spina Bifida
Technology Networks A pair of English bulldog puppies are the first patients to be successfully treated with a unique therapy — a combination of surgery and stem cells — developed at the University of California, Davis, to help preserve lower-limb function in children … |
Technology Networks |
Stem Cell Treatment Helps Puppies With Spina Bifida
Technology Networks A pair of English bulldog puppies are the first patients to be successfully treated with a unique therapy — a combination of surgery and stem cells — developed at the University of California, Davis, to help preserve lower-limb function in children … |
ETHealthworld.com |
ICMR’s stem cell research guidelines soon to be released
ETHealthworld.com New Delhi: Indian Council of Medical Research (ICMR) will soon release the final document on guidelines for stem cell research, the draft of which was available on the ICMR and the DBT (Department of Biotechnology) websites for public reviews till July … |
|
Gilead buys into CAR–T with $11.9bn deal for Kite
PharmaTimes Gilead Sciences is buying Kite Pharma in a deal worth $11.9 billion, securing itself access to the latter’s experimental CAR-T therapy axicabtagene ciloleucel and wider cancer pipeline. … involves drawing T cells from a patient’s blood and … So Long To KITE; JUNO, CLLS, MBIO, BLCM Are Sympathy Plays; PGNX Catches EyeNasdaq |